Share This Page
Drugs in ATC Class C01DA
✉ Email this page to a colleague
Drugs in ATC Class: C01DA - Organic nitrates
| Tradename | Generic Name |
|---|---|
| BIDIL | hydralazine hydrochloride; isosorbide dinitrate |
| ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE | hydralazine hydrochloride; isosorbide dinitrate |
| DILATRATE-SR | isosorbide dinitrate |
| ISORDIL | isosorbide dinitrate |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class C01DA (Organic nitrates): Which patents still block generics and how exclusivity timelines shape pricing?
Organic nitrates in ATC Class C01DA are largely off-patent for core actives such as glyceryl trinitrate (GTN/nitroglycerin), isosorbide dinitrate (ISDN), and isosorbide mononitrate (ISMN). Patent estates today are dominated by (1) secondary patents (crystalline forms, polymorphs, particle size, salts/co-crystals, permeation enhancers), (2) delivery-system patents (transdermal patches, OROS or osmotic systems, sustained-release matrices), and (3) process/manufacturing claims. The economic picture is shaped by (a) high generic penetration, (b) multiple dosing form pathways, and (c) local reimbursement and formulary preference for specific brands and delivery systems rather than for the active ingredient.
Below is a practical market and IP map of what still matters for exclusivity, where patent barriers typically persist, and how generics enter when Orange Book-style listings and EU SPCs or national registrations exist.
How do organic nitrates in ATC C01DA make money today, and what market dynamics drive volume vs pricing?
What is the demand engine for C01DA organic nitrates?
C01DA organic nitrates are used across:
- Chronic stable angina (prophylaxis)
- Acute angina (sub-lingual/spray GTN)
- Heart failure and ischemia-related syndromes in some markets via specific products or protocols
- Secondary use in peri-procedural vasodilation in certain settings
Commercial dynamics skew toward:
- Fast onset products (sub-lingual GTN, sprays) where switching costs are lower
- Sustained-release formulations (oral ISMN/ISDN; GTN patches; modified-release tablets) where substitution is constrained by perceived duration of action, tolerability, and prescriber familiarity
Why does the active ingredient matter less than the formulation?
For most jurisdictions, the foundational active-ingredient compositions are long expired. Price differentiation shifts to:
- Controlled-release kinetics (avoid “head-start” and late “end-of-dose” angina)
- Patient adherence (patches, long-acting tablets)
- Tolerability improvements (GI profile for oral sustained-release; skin tolerability for transdermals)
- Manufacturing reproducibility and bioequivalence with narrow therapeutic windows in practice
Typical market structure
- Institutional formularies favor brands with consistent kinetics and documented substitution experience.
- Retail penetration is strong for legacy generics; brand positioning often survives only where payers require a specific delivery system.
Which organic nitrates sit at the center of ATC C01DA, and how do their patent estates usually differ?
Core actives under C01DA
- Glyceryl trinitrate (GTN / nitroglycerin)
- Isosorbide dinitrate (ISDN)
- Isosorbide mononitrate (ISMN)
Estate pattern by active ingredient
Glyceryl trinitrate
- Patent activity historically concentrated in transdermal delivery (patches, controlled release systems) and sublingual/spray dosing forms.
- Modern “still-protected” products are often locked behind delivery-system claims or specific patch formulations rather than composition-of-matter on nitroglycerin.
Isosorbide dinitrate and mononitrate
- Patent focus tends toward sustained-release matrices, particle engineering, and release-rate control.
- Many “generic” barriers are mechanical: if a generic does not replicate dissolution profile and manufacturing method, bioequivalence may not be attainable on the first attempt.
What patents protect organic nitrates (GTN, ISDN, ISMN) and their delivery systems after active ingredient expiration?
Because core actives are older, protection tends to concentrate in the “second layer” IP. Common claim categories that can extend exclusivity in C01DA:
1) Formulation patents
- Sustained-release tablet matrices
- Polymer blends controlling hydration and drug diffusion
- Co-processed excipient systems affecting release
- Specific ratios of active to rate-controlling agents
2) Solid-state patents
- Polymorphs and hydrates
- Crystalline form specifications
- Particle size distributions and manufacturing-induced morphology
3) Manufacturing/process patents
- Granulation and milling process conditions
- Drying steps affecting internal structure and dissolution
- Scale-up process windows
4) Delivery-device and membrane patents (GTN patches)
- Membrane composition and thickness ranges
- Permeation enhancer systems
- Backing layers and laminate structures controlling flux
5) Method-of-use patents
- Sometimes appear in secondary studies tied to specific clinical protocols, but for older nitrates, these are less likely to be enforceable today without active clinical-specific claims.
When do organic nitrates lose exclusivity: a practical timeline for active ingredients vs delivery systems?
Active ingredient baseline
For GTN, ISDN, and ISMN, composition-of-matter protection generally predates modern generic competition by decades. As a result:
- Active-ingredient expiration is not the main driver of today’s barriers.
- Exclusivity windows, where they exist, typically come from formulation patents, SPCs, or device/delivery system IP.
Exclusivity timeline by “patent type”
- Older core composition claims: expired in most markets long ago
- Newer formulation/device patents: may still be active depending on filing years and jurisdictions
- SPCs: can push protection out for specific patents that were authorized and for which SPC criteria were met
- Paediatric extensions: occasional tail risk for EU-originated dossiers
What generic entry risks exist for C01DA nitrates: Paragraph IV-style risk in the real world?
How generic challenges usually work
In practice for C01DA:
- Generic entry often proceeds under ANDA bioequivalence rather than via complex patent litigation.
- When patent listings exist and are enforceable, the risk resembles “Paragraph IV” dynamics:
- Filing with a challenge
- Triggering an automatic stay in the US (if a statutory trigger is met)
- Negotiation of a settlement or covenant not to sue
Where litigation risk is concentrated
- Specific sustained-release products (where dissolution profile is central to equivalence)
- Transdermal GTN patches (where permeation and membrane engineering can be hard to replicate)
What is the Orange Book status of organic nitrates like GTN, ISMN, and ISDN?
A complete Orange Book mapping requires the exact drug list and NDC-linked entries. Under this constraint, only the general status pattern is accurate:
- Most GTN/ISMN/ISDN actives are not protected by active ingredient composition in the US.
- Orange Book listings, where present, are commonly tied to formulation or manufacturing patents for particular brand strengths and dosage forms.
This means the “patent look-through” by dosage form is decisive:
- A generic may be free to market one dosage form while being blocked for another if a separate formulation patent is still listed.
How does patent strength for delivery-system nitrates compare with simple oral generics?
Patent strength tends to be higher for delivery systems
- Sustained-release and transdermal systems can embed:
- narrow parameter ranges for excipients or membranes
- non-obvious manufacturing steps
- structural claims that are difficult to design around without performance risk
Simple oral immediate-release has lower IP density
- Immediate-release nitrates usually have fewer claim footholds in active litigation.
- Bioequivalence for simple forms is more straightforward, so generic entry is less sensitive to claim workarounds.
Which companies are challenging organic nitrate patents, and where do settlements typically land?
At a market level, enforcement and settlement are most likely where:
- There is a still-active formulation patent tied to a commercially meaningful brand
- A generic’s proposed product has a release profile or flux profile that may not be straightforward to distinguish at the claim level
- The brand holds a meaningful formulary position
In C01DA, the observed settlement pattern typically trends toward:
- Design-around agreements for release rate or membrane composition
- Licensing for the delivery system (not the active ingredient)
- Launch timing settlements that trade early entry for avoided litigation cost
How do EU and national extensions (SPCs) affect organic nitrate exclusivity compared with the US?
For older actives, SPC impact depends on:
- Whether a protected patent was eligible and properly linked to the marketing authorization
- Whether the SPC was granted for a specific product and patent basis
In the EU:
- Even when composition-of-matter is expired, SPCs can extend protection for the authorized product if a qualifying basic patent exists.
- Many enforcement disputes in C01DA therefore hinge on SPC scope and which claims are considered covered.
Which formulations are most often protected for C01DA: transdermal patches vs sustained-release tablets?
Transdermal GTN patches
Common protected elements:
- laminate structure
- membrane material selection and thickness
- permeation enhancer systems
- control of flux rate stability over wear time
Oral sustained-release ISMN/ISDN
Common protected elements:
- release-modifying excipient systems
- polymer/drug ratio ranges
- matrix architecture influencing hydration and diffusion
- manufacturing parameters impacting dissolution
What manufacturing and IP barriers can block generic substitution in organic nitrates?
Bioequivalence barriers
- Sustained-release products require tight matching of:
- dissolution kinetics
- plasma concentration time profiles
- Cmax and time-to-Cmax
- Even with bioequivalence approval, litigation may attack patent infringement rather than regulatory failure.
Design-around complexity
For transdermals:
- replicating flux and duration without copying structural claims is hard. For sustained-release:
- release profile depends on microstructure and excipient engineering; copying may inadvertently infringe narrow ranges.
What does the competitive landscape look like across geographies for C01DA nitrates?
US
- Highly genericized oral nitrate market for long-standing strengths and release types.
- Payer-driven switching supports generic entry where no enforceable formulation/device patents exist.
EU
- Greater role for SPCs and national procedural differences.
- Product-specific enforceability often dominates: one brand’s patch or sustained-release tablet may be blocked while other forms compete.
Emerging markets
- Competition can be faster due to weaker enforcement.
- Still, brand-specific delivery systems can remain protected via local patents if filed and maintained.
How can you quantify revenue exposure from patent cliffs in organic nitrates?
Revenue exposure mechanism
Revenue risk is not driven by active-ingredient expiration. It is driven by:
- the end of the last enforceable formulation/device patent tied to a specific brand product line
- the end of SPC/SPP-related tail protection (EU)
- the expiration of listed Orange Book formulation/manufacturing patents (US) for a specific dosage form
Practical quantification method
Use a dosage-form segmentation approach:
- Map brand revenue by GTN patch vs sustained-release oral vs immediate-release SL/spray.
- For each product, list patent types likely to survive:
- formulation/device
- solid-state
- manufacturing
- Identify the “last expiring” claim cluster.
- Model launch timing sensitivity to potential litigation.
Key Takeaways
- ATC C01DA organic nitrates are mostly off-patent on core actives; today’s exclusivity is driven by formulation, solid-state, process, and delivery-system patents.
- Transdermal GTN patches and oral sustained-release ISMN/ISDN carry the highest residual IP density and the strongest generic design-around barriers.
- Market dynamics favor delivery-system consistency over active ingredient novelty, keeping brand value even when active-ingredient patents expire.
- For generic planning, the real risk is product-specific formulation/device patent coverage rather than active-ingredient composition claims.
- Patent cliffs for investors and strategics should be modeled at the dosage-form and product line level, using the last enforceable formulation/device/possibly SPC tail for that specific brand.
FAQs
1) What patent types most commonly survive for GTN transdermal patches in ATC C01DA?
Delivery and membrane/permeation flux control claims, plus laminate and enhancer system patents.
2) Do isosorbide mononitrate sustained-release tablets have higher litigation risk than immediate-release forms?
Yes, because sustained-release kinetics depend on matrix and microstructure claims that are harder to replicate without infringing.
3) How should a generic developer design around formulation patents for ISMN/ISDN sustained-release products?
By targeting different release-rate mechanisms through distinct excipient systems and manufacturing process logic that avoids copying narrow parameter ranges.
4) What drives payer preference in organic nitrate markets if most active ingredients are generic?
Consistency of duration of effect, tolerability, and the specific delivery system’s established clinical and formulary position.
5) Are EU SPCs the main reason a branded organic nitrate can remain on formulary after active ingredient expiry?
Often, yes, when an eligible basic patent was tied to the marketing authorization and the SPC scope covers key product claims.
References (APA)
- ATC Classification System. World Health Organization. (Accessed via WHO ATC).
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US FDA. (Orange Book database, accessed via US FDA).
- European Medicines Agency. Supplementary Protection Certificates (SPC) framework information. EMA.
More… ↓
